Table 1.
Correlation between AGS, AGR and clinicopathological parameters in 404 patients with chronic HF
| Variables | AGS (high=260, low=144) | AGR (high=189, low=215) | ||||
| High (1–2) | Low (0) | P values | High (>1.48) | Low (≤1.48) | P values | |
| Age (years) | 63.82±15.63 | 60.67±15.45 | 0.051 | 59.46±15.34 | 65.41±15.34 | <0.001 |
| Gender | ||||||
| Male | 133 (51.2%) | 87 (60.4%) | 0.073 | 111 (58.7%) | 109 (51.2%) | 0.129 |
| Albumin (g/dL) | 37.8 (26.8–47.1) | 36.0 (24.2–45.1) | 0.026 | 36.3 (26.1–46.3) | 38.2 (25.7–47.5) | 0.017 |
| Hypertension | 107 (41.2%) | 59 (41.0%) | 0.972 | 78 (41.3%) | 88 (41.3%) | 0.993 |
| Diabetes mellitus | 80 (30.8%) | 32 (22.2%) | 0.066 | 42 (22.2%) | 70 (32.9%) | 0.018 |
| CKD | 32 (12.3%) | 7 (4.9%) | 0.015 | 16 (8.5%) | 23 (10.8%) | 0.430 |
| History of HF | 185 (71.2%) | 110 (76.4%) | 0.256 | 145 (76.7%) | 148 (69.5%) | 0.103 |
| VHD | 35 (13.5%) | 18 (12.5%) | 0.784 | 24 (12.7%) | 29 (13.6%) | 0.786 |
| CHD | 118 (45.4%) | 68 (47.2%) | 0.723 | 75 (39.7%) | 110 (51.6%) | 0.016 |
| DCM | 39 (15.0%) | 33 (22.9%) | 0.046 | 47 (24.9%) | 25 (11.7%) | 0.001 |
| HCM | 7 (2.7%) | 2 (1.4%) | 0.395 | 5 (2.6%) | 4 (1.9%) | 0.604 |
| HHD | 5 (1.9%) | 5 (3.5%) | 0.337 | 5 (2.6%) | 5 (2.3%) | 0.848 |
| AF | 81 (31.2%) | 40 (27.8%) | 0.478 | 60 (31.7%) | 60 (28.2%) | 0.434 |
| BNP (pg/mL) | 3948.5 (500.7–18 807.6) | 2643.0 (409.6–12 089.1) | <0.001 | 2881.0 (532.4–20 725.8) | 4155.5 (445.2–17 685.2) | <0.001 |
| Echocardiography findings | ||||||
| IVST (mm) | 10.0 (7.8–13.0) | 9.7 (8.0–13.4) | 0.027 | 10.0 (8.0–14.0) | 10.0 (7.7–13.0) | 0.813 |
| PWT (mm) | 9.0 (8.0–12.0) | 9.0 (7.2–12.9) | 0.172 | 9.0 (2.2–12.8) | 9.0 (8.0–11.0) | 0.423 |
| LVDv (mL) | 152.0 (71.6–347.6) | 170.0 (72.6–346.0) | 0.014 | 150.5 (72.0–365.7) | 170.0 (67.8–343.2) | 0.023 |
| LVSv (mL) | 75.5 (27.0–225.6) | 98.0 (27.0–232.1) | 0.007 | 95.0 (26.4–230.0) | 74.5 (27.0–231.1) | 0.019 |
| LVEF (%) | 48.0 (28.0–67.5) | 45.0 (27.0–64.0) | 0.031 | 45.0 (27.0–65.0) | 48.0 (28.0–67.0) | 0.086 |
| LAD (mm) | 40.0 (29.0–58.4) | 42.0 (28.3–63.7) | 0.047 | 42.0 (29.4–62.2) | 39.0 (29.0–60.6) | 0.032 |
| Medications, n (%) | ||||||
| Beta-blocker | 152 (58.5%) | 99 (68.8%) | 0.041 | 130 (68.8%) | 120 (56.3%) | 0.010 |
| CCB | 57 (21.9%) | 31 (21.5%) | 0.927 | 43 (22.8%) | 45 (21.1%) | 0.694 |
| Statins | 120 (46.2%) | 70 (48.6%) | 0.636 | 92 (48.7%) | 97 (45.5%) | 0.529 |
| ARB | 83 (31.9%) | 41 (28.5%) | 0.471 | 63 (33.3%) | 61 (28.6%) | 0.309 |
| ACE-I | 74 (28.5%) | 69 (47.9%) | <0.001 | 83 (43.9%) | 59 (27.7%) | 0.001 |
ACE-I, ACE inhibitor; AF, atrial fibrillation; AGR, albumin to globulin ratio; AGS, albumin-globulin score; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; CCB, calcium-channel blocker; CHD, coronary heart disease; CKD, chronic kidney disease; DCM, idiopathic dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HF, heart failure; HHD, hypertensive heart disease; IVST, interventricular septum thickness; LAD, left atrial dimension; LVDv, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVSv, left ventricular end-systolic volume; PWT, posterior wall thickness; VHD, valvular heart disease.